Document is current
Any future updates will be listed below
-
Authors
Steiner, Stefan
Gerendas, Bianca S.
Deak, Gabor
Leingang, Oliver
Whitby, Ariadne
Bogunovic, Hrvoje
Reiter, Gregor S.
Schmidt-Erfurth, Ursula
- License Information
-
More Information
Article History
Received: 22 October 2024
Accepted: 16 March 2026
First Online: 31 March 2026
Declarations
:
: A.W. is an employee of RetInSight and does not hold any equity or shares in the company. B.S.G. is a scientific consultant for Roche, Zeiss, Bayer, and Abbvie. G.S.R is a scientific consultant for Apellis, Bayer, Boehringer Ingelheim and Roche and received research funds from RetInSight. H.B. received research funds from Heidelberg Engineering and Apellis. O.L. is an employee of RetInSight and does not hold any equity or shares in the company. U.S.-E. is a scientific consultant for Apellis, Bayer, AbbVie, Medscape, Allergan, Roche, Boehringer, Aviceda, Annexon, Topcon, Alkeus and received research funds by Genentech, Kodiak, Novartis, RetInSight, Apellis Pharmaceuticals.
: The study received approval from the Ethics Committee of the Medical University of Vienna. It was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.
